Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Takeover offer for Recordati boosts CVC shares 3.3%

CVC, together with Groupe Bruxelles Lambert, made a cash offer of €10.7 billion for the Italian pharmaceutical group Recordati with the aim of taking the company private. The announcement lifted CVC’s share price by about 3.3% on Friday, marking its best trading day since the end of April. RBC analysts see the rationale for the deal in increased investment in research and development and in future mergers and acquisitions. » Mais em de.investing.com
Recordati: Q1 sales rise 4.9% to €730m – shares gain 3.39%

Recordati reports Q1 2026 sales of €730m (+4.9%) and an EBITDA of €284m with a margin of 39.7%. Adjusted net profit was €188m (+7.2%); the US business grew by 25.1%, while negative currency effects weighed on sales by 4.3%. The shares rose 3.39% after the figures; for 2026 the company expects net sales between €2.73bn and €2.80bn and EBITDA of €995m to €1.03bn. » Mais em de.investing.com
CVC considers sale of parts of Recordati after potential takeover

CVC Capital Partners is considering, in the event of a successful takeover of Recordati for €10.9 billion, selling individual business units—specifically the rare diseases division—and other assets. The firm aims to take Recordati private after the acquisition to gain greater flexibility for a realignment and to unlock value. Plans are at an early stage and details may still change. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, Recordati Industria Chimica e Farma já distribuiu € 0,71 em dividendos. A última distribuição ocorreu em maio.

Dados financeiros da empresa

No último trimestre, Recordati Industria Chimica e Farma registou receitas de € 697,36 mi e um ganho líquido de € 116,61 mi

(EUR)	junho de 2026	YoY
Receitas	697,36 mi	8,30%
Ganho bruto	497,97 mi	17,49%
Ganho líquido	116,61 mi	28,03%
EBITDA	256,61 mi	31,83%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 10,65 bi
Número de ações	203,46 mi
Máximo/mínimo de 52 semanas	€ 54,45 - € 43,76
Rentabilidade de dividendos	2,56%
Dividendos TTM	€ 1,34
Beta	0,53
PER (PE Ratio)	21,54
PEG (PEG Ratio)	0,95
P/VC (PB Ratio)	5,00
P/V (PS Ratio)	3,94

Perfil da empresa

Recordati Industria Chimica e Farmaceutica S.p.A. ist zusammen mit seinen Tochtergesellschaften in der Forschung, Entwicklung, Herstellung, Vermarktung und dem Verkauf von Arzneimitteln weltweit tätig. Das Unternehmen bietet Arzneimittel in verschiedenen therapeutischen Bereichen an, darunter Herz-Kreislauf, Dermatologie, rezeptfreie Arzneimittel, Urologie, Antiinfektiva, zentrales Nervensystem, Magen-Darm-Trakt, Gynäkologie und Geburtshilfe, Muskel-Skelett-Erkrankungen und Analgetika, Ernährung und verwandte Produkte, Kosmetika, Nahrungsergänzungsmittel, Medizinprodukte, Allergien, Endokrinologie, Atemwegserkrankungen, Schmerztherapie/Entzündungen, Generika, fiebersenkende Mittel und Erkältungspräparate, Onkologie sowie Hals-, Nasen- und Ohrenheilkunde. Darüber hinaus bietet das Unternehmen Produkte für seltene Krankheiten sowie pharmazeutische Chemikalien wie chemische Synthesen, pharmazeutische Wirkstoffe und Zwischenprodukte an. Das Unternehmen wurde 1926 gegründet und hat seinen Hauptsitz in Mailand, Italien. Recordati Industria Chimica e Farmaceutica S.p.A. ist als Tochtergesellschaft von Rossini S.à R.L. tätig.

Nome	Recordati Industria Chimica e Farma
CEO	Robert Koremans
Sede	Milan, mi Itália
Site	recordati.com
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	18/09/2020
Colaboradores	4.693